Literature DB >> 26067435

Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression.

Boadie W Dunlop1, Mary E Kelley1, Callie L McGrath1, W Edward Craighead1, Helen S Mayberg1.   

Abstract

A putative right anterior insula metabolism biomarker predictive of treatment outcomes was retrospectively applied to 30 depressed psychotherapy--or escitalopram-treated nonremitters who entered combination treatment. Patients whose added treatment matched the biomarker-indicated treatment remitted more often than biomarker-mismatched patients.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26067435      PMCID： PMC4788472          DOI： 10.1176/appi.neuropsych.14030048

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


  8 in total

1.  Neural systems supporting interoceptive awareness.

Authors:  Hugo D Critchley; Stefan Wiens; Pia Rotshtein; Arne Ohman; Raymond J Dolan
Journal:  Nat Neurosci       Date:  2004-01-18       Impact factor: 24.884

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  Mindfulness-based training attenuates insula response to an aversive interoceptive challenge.

Authors:  Lori Haase; Nate J Thom; Akanksha Shukla; Paul W Davenport; Alan N Simmons; Elizabeth A Stanley; Martin P Paulus; Douglas C Johnson
Journal:  Soc Cogn Affect Neurosci       Date:  2014-04-08       Impact factor: 3.436

4.  Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: a potential marker for response?

Authors:  Charles R Conway; John T Chibnall; Sunil Gangwani; Mark A Mintun; Joseph L Price; Tamara Hershey; Luis A Giuffra; Richard D Bucholz; Jon J Christensen; Yvette I Sheline
Journal:  J Affect Disord       Date:  2012-03-05       Impact factor: 4.839

5.  Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder.

Authors:  Boadie W Dunlop; Mary E Kelley; Tanja C Mletzko; Cristina M Velasquez; W Edward Craighead; Helen S Mayberg
Journal:  J Psychiatr Res       Date:  2011-11-26       Impact factor: 4.791

6.  Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study.

Authors:  Paul J Carlson; Nancy Diazgranados; Allison C Nugent; Lobna Ibrahim; David A Luckenbaugh; Nancy Brutsche; Peter Herscovitch; Husseini K Manji; Carlos A Zarate; Wayne C Drevets
Journal:  Biol Psychiatry       Date:  2013-03-27       Impact factor: 13.382

7.  Pretreatment brain states identify likely nonresponse to standard treatments for depression.

Authors:  Callie L McGrath; Mary E Kelley; Boadie W Dunlop; Paul E Holtzheimer; W Edward Craighead; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2013-12-19       Impact factor: 13.382

8.  Toward a neuroimaging treatment selection biomarker for major depressive disorder.

Authors:  Callie L McGrath; Mary E Kelley; Paul E Holtzheimer; Boadie W Dunlop; W Edward Craighead; Alexandre R Franco; R Cameron Craddock; Helen S Mayberg
Journal:  JAMA Psychiatry       Date:  2013-08       Impact factor: 21.596
  8 in total
  14 in total

1.  An active inference theory of allostasis and interoception in depression.

Authors:  Lisa Feldman Barrett; Karen S Quigley; Paul Hamilton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-10-10       Impact factor: 6.237

2.  Brain 18F-FDG PET/CT findings in a case of genetic Creutzfeldt-Jakob disease due to V203I heterozygous mutation in the PRNP gene.

Authors:  A Cistaro; L Cassalia; C Ferrara; C Atzori; D Vai; N Quartuccio; P Fania; G P Vaudano; D Imperiale
Journal:  J Neurol       Date:  2016-11-14       Impact factor: 4.849

3.  Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Authors:  Boadie W Dunlop; Devon LoParo; Becky Kinkead; Tanja Mletzko-Crowe; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  Am J Psychiatry       Date:  2019-02-15       Impact factor: 18.112

4.  Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.

Authors:  Boadie W Dunlop; Justin K Rajendra; W Edward Craighead; Mary E Kelley; Callie L McGrath; Ki Sueng Choi; Becky Kinkead; Charles B Nemeroff; Helen S Mayberg
Journal:  Am J Psychiatry       Date:  2017-03-24       Impact factor: 18.112

5.  Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI.

Authors:  Natania A Crane; Lisanne M Jenkins; Runa Bhaumik; Catherine Dion; Jennifer R Gowins; Brian J Mickey; Jon-Kar Zubieta; Scott A Langenecker
Journal:  Brain       Date:  2017-01-24       Impact factor: 13.501

6.  Mapping Neural Circuit Biotypes to Symptoms and Behavioral Dimensions of Depression and Anxiety.

Authors:  Andrea N Goldstein-Piekarski; Tali M Ball; Zoe Samara; Brooke R Staveland; Arielle S Keller; Scott L Fleming; Katherine A Grisanzio; Bailey Holt-Gosselin; Patrick Stetz; Jun Ma; Leanne M Williams
Journal:  Biol Psychiatry       Date:  2021-07-11       Impact factor: 12.810

Review 7.  Treatment resistant depression: A multi-scale, systems biology approach.

Authors:  Huda Akil; Joshua Gordon; Rene Hen; Jonathan Javitch; Helen Mayberg; Bruce McEwen; Michael J Meaney; Eric J Nestler
Journal:  Neurosci Biobehav Rev       Date:  2017-08-30       Impact factor: 8.989

Review 8.  Defining biotypes for depression and anxiety based on large-scale circuit dysfunction: a theoretical review of the evidence and future directions for clinical translation.

Authors:  Leanne M Williams
Journal:  Depress Anxiety       Date:  2016-09-21       Impact factor: 6.505

9.  Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges.

Authors:  Mary E Kelley; Ki Sueng Choi; Justin K Rajendra; W Edward Craighead; Jeffrey J Rakofsky; Boadie W Dunlop; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2021-02-26       Impact factor: 12.810

10.  Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder.

Authors:  Ashish K Sahib; Joana R A Loureiro; Megha M Vasavada; Antoni Kubicki; Shantanu H Joshi; Kai Wang; Roger P Woods; Eliza Congdon; Danny J J Wang; Michael L Boucher; Randall Espinoza; Katherine L Narr
Journal:  Eur Neuropsychopharmacol       Date:  2020-02-12       Impact factor: 5.415
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.